Robert C. Andrews;Ghassan Qabaja;Xiao-Chuan Guo;Anitha Hari;Adnan M.M. Mjalli;Kwasi S. Avor;David R. Jones;Xin Chen;Ramesh Gopalaswamy;Suparna Gupta
发明人:
Adnan M.M. Mjalli,Robert C. Andrews,Ramesh Gopalaswamy,Anitha Hari,Kwasi S. Avor,Ghassan Qabaja,Xiao-Chuan Guo,Suparna Gupta,David R. Jones,Xin Chen
申请号：
US13270208
公开号：
US20120088778A1
申请日:
2011.10.10
申请国别(地区):
US
年份:
2012
代理人:
摘要：
This invention provides certain compounds, methods of their preparation, pharmaceutical compositions comprising the compounds, and their use in treating human or animal disorders. The compounds of the invention are useful as modulators of the interaction between the receptor for advanced glycated end products (RAGE) and its ligands, such as advanced glycated end products (AGEs), S100/calgranulin/EN-RAGE, β-amyloid and amphoterin, and for the management, treatment, control, or as an adjunct treatment for diseases in humans caused by RAGE. Such diseases or disease states include acute and chronic inflammation, the development of diabetic late complications such as increased vascular permeability, nephropathy, atherosclerosis, and retinopathy, the development of Alzheimer's disease, erectile dysfunction, and tumor invasion and metastasis.
